MYOCET LIPOSOMAL
50MG INF PSD LQC DIS 2XSET
Announcement of launch, break or close-out of marketing of a medicinal product
Type of announcement | Effective date | Alternate medicines ? | Reason for interruption/cessation of marketing | Estimated renewal date |
---|---|---|---|---|
Interruption of marketing | 01.07.2022 |
0027432 Lék obtížně nahraditelný (dle uvážení lékaře) |
Procedural/regulatory reasons | 31.10.2022 |
Resumption of marketing | 03.12.2018 | |||
Interruption of marketing | 01.12.2018 | Nahraditelný pegylovaným lipozomálním doxorubicinem (Caelyx) | Capacity/distribution reasons | 2019 |
Resumption of marketing | 15.04.2018 | |||
Interruption of marketing | 20.07.2017 | Lék se stejnými indikacemi | ||
Resumption of marketing | 20.04.2012 | |||
Interruption of marketing | 27.02.2012 | lék se stejnými indikacemi | ||
Resumption of marketing | 24.02.2012 |
All reports are available in the Overview.